Age
Item
18 years of age
boolean
C0001779 (UMLS CUI [1])
Acute leukemia in relapse | Acute leukemia refractory
Item
histologically or cytologically documented relapsed or refractory acute leukemia
boolean
C2367453 (UMLS CUI [1])
C0085669 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
Standard therapy benefit Unlikely | Standard therapy Refused
Item
unlikely to benefit from standard therapy in the opinion of the investigator or refuse standard therapy
boolean
C2936643 (UMLS CUI [1,1])
C0814225 (UMLS CUI [1,2])
C0750558 (UMLS CUI [1,3])
C2936643 (UMLS CUI [2,1])
C1705116 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Renal function | Liver function
Item
adequate renal and hepatic function
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
Criteria Hematologic Absent | White Blood Cell Count procedure | Hemoglobin | Blood Platelets
Item
no hematologic criteria for wbc, hbg or platelets
boolean
C0243161 (UMLS CUI [1,1])
C0205488 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0023508 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
C0005821 (UMLS CUI [4])
HIV negative | Hepatitis B surface antigen negative | Hepatitis C test negative
Item
negative virology screen for hiv, hepatitis b surface antigen & hepatitis c
boolean
C0481430 (UMLS CUI [1])
C0919711 (UMLS CUI [2])
C1619717 (UMLS CUI [3])
Childbearing Potential Serum pregnancy test negative
Item
female patients of childbearing potential must have a negative serum pregnancy test
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
Gender | Agreement Barrier Contraception | Agreement Chemical contraception
Item
male & female patients must agree to use a medically acceptable barrier and/or chemical contraceptive method during the study and for a minimum of 3 months afte the last dose of study treatment.
boolean
C0079399 (UMLS CUI [1])
C0680240 (UMLS CUI [2,1])
C0004764 (UMLS CUI [2,2])
C0680240 (UMLS CUI [3,1])
C1868784 (UMLS CUI [3,2])
Status post Blood Transplantation | Status post Bone Marrow Transplantation | Absolute CD8 count Circulating blood
Item
patients post blood or marrow transplant should demonstrate a circulating cd8 count of at lest 200 cells/ul
boolean
C0231290 (UMLS CUI [1,1])
C0005767 (UMLS CUI [1,2])
C0040732 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0005961 (UMLS CUI [2,2])
C1277777 (UMLS CUI [3,1])
C0440738 (UMLS CUI [3,2])
Central nervous system leukaemia
Item
active cns leukemia
boolean
C1332884 (UMLS CUI [1])
Chemotherapy | Therapeutic radiology procedure | Immunotherapy
Item
current concomitant chemotherapy, radiation therapy or immunotherapy
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
Investigational New Drugs | Relationship JVRS-100
Item
receipt of any investigational agent within 28 days of first dose of jvrs-100
boolean
C0013230 (UMLS CUI [1])
C0439849 (UMLS CUI [2,1])
C2830046 (UMLS CUI [2,2])
Toxicity persistent CTCAE Grades | Etiology Cancer treatment
Item
persistent clinically significant toxicity from prior anticancer therapy that is > grade 2 (nci ctcae v3.0)
boolean
C0600688 (UMLS CUI [1,1])
C0205322 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
C0015127 (UMLS CUI [2,1])
C0920425 (UMLS CUI [2,2])
Bone Marrow Transplantation | Stem cell transplant | Relationship JVRS-100
Item
bone marrow or stem cell transplant within 3 months prior to first dose of jvrs-100
boolean
C0005961 (UMLS CUI [1])
C1504389 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C2830046 (UMLS CUI [3,2])
Immunosuppressive Agents chronic | Relationship JVRS-100 | Inhaled steroids allowed | Nasal Sprays allowed | Eye Drops allowed | Topical Cream allowed
Item
chronic administration of immunosuppressive agents within 14 days of first dose of jvrs-100. use of inhaled steroids, nasal sprays, eye drops, and topical creams for small body areas is allowed.
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0439849 (UMLS CUI [2,1])
C2830046 (UMLS CUI [2,2])
C2065041 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C2608293 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
C0015399 (UMLS CUI [5,1])
C0683607 (UMLS CUI [5,2])
C0991551 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Pregnancy | Breast Feeding
Item
pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Cancer Other | Exception Leukemia | Basal cell carcinoma Excluded | Squamous cell carcinoma of skin Excluded | Carcinoma in situ of uterine cervix Excluded
Item
history of prior malignancy other than leukemia within the past 5 years, excluding basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0023418 (UMLS CUI [2,2])
C0007117 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0553723 (UMLS CUI [4,1])
C0332196 (UMLS CUI [4,2])
C0851140 (UMLS CUI [5,1])
C0332196 (UMLS CUI [5,2])
Systemic mycosis | Bacterial Infection Systemic | Virus Disease Systemic
Item
patients with a systemic fungal, bacterial, viral, or other infection not controlled
boolean
C0553576 (UMLS CUI [1])
C0004623 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0042769 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
Condition compromises Patient safety | Condition compromises Compliance behavior | Condition Interferes with Informed Consent | Condition Interferes with Study Subject Participation Status | Condition Interferes with Follow-up | Condition Interferes with Interpretation Research results
Item
any condition which, in the opinion of the investigator, would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
boolean
C0348080 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C1321605 (UMLS CUI [2,3])
C0348080 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0021430 (UMLS CUI [3,3])
C0348080 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C2348568 (UMLS CUI [4,3])
C0348080 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C3274571 (UMLS CUI [5,3])
C0348080 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0459471 (UMLS CUI [6,3])
C0683954 (UMLS CUI [6,4])